COVID-19 News

BARDA and DoD partner to buy 1.7M doses of Merck COVID-19 drugs

The Biden Administration announced on June 9 that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA). The Biomedical Advanced Research and Development Authority (BARDA) collaborated with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army Contracting Command on the $1.2 billion purchase agreement.

Molnupiravir (MK-4482) is designed to induce viral genome copying errors to prevent the virus from replicating in the human body, and evidence to date from clinical trials in patients with COVID-19 suggests that molnupiravir may reduce replication of the SAR-CoV-2 virus.

This treatment is being evaluated in an ongoing Phase 3 trial for its potential to reduce the risk of hospitalization or death in non-hospitalized patients who have symptoms for five days or less and are at high risk for severe illness. The trial plans to enroll a total of 1,850 patients globally with final data expected in the fall of 2021.

In studies, molnupiravir has demonstrated broad-spectrum activity against other viruses such as influenza, Ebola, and Venezuelan Equine Encephalitis virus, although molnupiravir has not been approved by the FDA for treatment of these diseases.

This agreement is part of the Biden Administration’s whole-of-government approach to develop new COVID-19 treatments and to respond to the health needs of the public through unprecedented partnership between agencies including the U.S. Department of Health and Human Services and the DoD. This approach leverages all expertise and resources available to respond to COVID-19 such as funding the development and manufacturing of therapeutics, including antivirals.

Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics. Merck is scaling up manufacturing while clinical trials are underway to deliver molnupiravir as quickly as possible, pending FDA EUA or approval. If FDA grants EUA or approval, the federal government will allocate molnupiravir to states and U.S. territories, and healthcare providers will be able to order the product directly from the distributor within those allocations.

Read more: https://www.medicalcountermeasures.gov/newsroom/2021/merck/